Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Fexuprazan in Erosive Gastroesophageal Reflux Disease
NCT03736369Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fexuprazan in erosive esophagitis (EE) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Cumulative healing rate of erosive esophagitis at 8 weeks. Started Dec 2018; status: completed.
02
Drugs
fexuprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT03736369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736369.